Carlos H. Schenck, a prominent sleep medicine specialist at the University of Minnesota, shares groundbreaking insights on daridorexant, a novel treatment for chronic insomnia. He discusses how this dual orexin receptor antagonist uniquely targets wakefulness, potentially transforming insomnia care. The conversation delves into its impressive efficacy—reporting 78% of patients experienced significant symptom relief—and examines the implications for future treatments, including its potential applications for narcolepsy and sleep apnea.